Detalhe da pesquisa
1.
A gain-of-function mutation in Nav1.6 in a case of trigeminal neuralgia.
Mol Med
; 22: 338-348, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27496104
2.
Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease.
J Immunol
; 183(5): 3454-62, 2009 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19648266
3.
Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 9(1): 62-73, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31650711
4.
Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.
ACS Med Chem Lett
; 11(9): 1678-1687, 2020 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32945812
5.
Dynamic balance of metabotropic inputs causes dorsal horn neurons to switch functional states.
Nat Neurosci
; 6(3): 274-81, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12592405
6.
Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience.
Trials
; 19(1): 704, 2018 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30587219
7.
The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity.
J Neurosci
; 26(50): 12852-60, 2006 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-17167076
8.
Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
Lancet Neurol
; 16(4): 291-300, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28216232
9.
TRPV1 antagonist, SB-366791, inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation.
Eur J Pharmacol
; 540(1-3): 73-81, 2006 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16737693
10.
Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia.
Trials
; 14: 402, 2013 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24267010